← Today’s ReceiptsOfficial public filing linked
Public-record receiptR-AROfficial filing linked
J. Hill disclosed SELL $PFE
Here’s the public record: who traded, what they disclosed, when it happened, how late it appeared, and what context is attached.
Trade range
$100K – $250K
Filed
2026-01-23
Trade date
2025-12-31
Disclosure lag
23 days after trade
Why this receipt matters
A quick read before you share it.
These are factual context points from the receipt and linked public-record data. They explain why the disclosure may be worth opening, not whether anyone acted improperly.
1The receipt links to an official public filing, so readers can verify the underlying disclosure before sharing.
2The filing appeared 23 days after trade, which helps separate trade timing from filing timing.
3The disclosed range is $100K – $250K, which is the public reporting band rather than an exact profit or loss figure.
44 nearby same-ticker disclosures appeared in the surrounding 30-day window.
5Committee context is available for J. Hill, but PoliWealth treats it as context - not proof of intent or wrongdoing.
6Related public-record context includes 33 lobbying filings and 1 federal contract record.
Source
Official filing ↗
Source: official House/Senate financial disclosure record · filing ID 20033661 · filed 2026-01-23 · disclosed 23d after transaction
Market context
Pfizer Inc.
Sector: Healthcare
Vs SPY: 3.4%
Factual flags
- 33 lobbying filings linked to this ticker.
- 1 federal contract record linked to this ticker.
- 4 nearby same-ticker disclosures in the surrounding 30-day window.
- Traded PFE 23d before lobbying filing by PFIZER INC. ($2,810,000)
- Trade upper bound: $250,000
- 5 trades filed on 2026-01-23 (batch dump)
Member trail
J. Hill
U.S. House · AR-2
House Permanent Select Committee on IntelligenceHouse Committee on Financial Services
Ticker trail
$PFE
Pfizer Inc.
Follow this tickerAlert me when this ticker gets a new congressional receipt. This page reports public disclosures and factual context only. It does not determine intent, is not an accusation, and is not investment advice.